BioPorto (BIOPOR.CO) Stock Analysis & AI Equity Report
BioPorto (BIOPOR.CO) overview
BioPorto (BIOPOR.CO) stock analysis and AI equity research. For the latest completed financial year, 2025, BioPorto reported revenue of DKK 40.3m and operating profit of DKK -86.1m; the year-end share price was 1.02 DKK and market capitalisation was DKK 548m. BioPorto is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get BioPorto's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About BioPorto
BioPorto A/S is an in vitro diagnostics company focused on biomarkers for early detection and management of acute kidney injury. Its main products are NGAL-based tests, including the CE-marked NGAL Test for Europe and the FDA-cleared ProNephro AKI test in the United States, alongside NGAL ELISA kits for research use.
Generate the BioPorto report
BioPorto is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for BioPorto and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on BioPorto
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.